Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2021-07-23 , DOI: 10.1111/apt.16544
Mathurin Fumery ₁ , Jérôme Filippi ₂ , Vered Abitbol ₃ , Amélie Biron ₄ , David Laharie ₅ , Melanie Serrero ₆ , Romain Altwegg ₇ , Yoram Bouhnik ₈ , Laurent Peyrin-Biroulet ₉ , Cyrielle Gilletta ₁₀ , Xavier Roblin ₁₁ , Guillaume Pineton de Chambrun ₇ , Lucine Vuitton ₁₂ , Anne Bourrier ₃ , Stephane Nancey ₁₃ , Jean-Marc Gornet ₃ , Stephane Nahon ₁₄ , Guillaume Bouguen ₁₅ , Stephanie Viennot ₁₆ , Maria Nachury ₁₇ , Aurelien Amiot ₁₈

Affiliation

Amiens, France.
Nice, France.
Paris, France.
Reims, France.
Bordeaux, France.
Marseille, France.
Montpellier, France.
Clichy, France.
Nancy, France.
Toulouse, France.
Saint-Etienne, France.
Besançon, France.
Lyon, France.
Montfermeil, France.
Rennes, France.
Caen, France.
Lille, France.
Creteil, France.

Phase III trials have demonstrated the efficacy and safety of ustekinumab in ulcerative colitis (UC), but few real-life long-term data are currently available.

中文翻译：